Neurofibromatosis type 1 (NF1) is a neurocutaneous syndrome with autosomal dominant patterns of inheritance.[1](#epi412085-bib-0001){ref-type="ref"} Affected individuals show characteristic skin lesions of café‐au‐lait spots, multiple tumors, and variable degree of mental disability with or without autistic features. The *NF1* gene is located at chromosome 17q11.2, encoding 2,839 amino acid protein neurofibromin.[2](#epi412085-bib-0002){ref-type="ref"} *NF1* mutations cause the hyperactive extracellular signal‐regulated kinase (ERK) pathway, thereby leading to accelerated cell growth and tumor formation.[3](#epi412085-bib-0003){ref-type="ref"} Hyperactive signals in synaptic ERK pathways are associated with both epilepsy and mental development in childhood.[4](#epi412085-bib-0004){ref-type="ref"} Previous studies demonstrated that the prevalence (0.76%) of infantile spasm (IS) or early‐onset epileptic encephalopathy (EOEE) in NF1 has been reported to be higher than those (0.02--0.05%) in general populations.[5](#epi412085-bib-0005){ref-type="ref"} Neuroimaging studies also revealed that cortical and subcortical lesions were occasionally found in NF1 patients.[6](#epi412085-bib-0006){ref-type="ref"} However, specific brain lesions or genetic backgrounds have not been disclosed for NF1 in the majority of cases with IS/EOEE. We experienced a case of a 45‐year‐old female with NF1, EOEE, and severe developmental delay. Atypical phenotypes in the present case were studied on the basis of genetic as well as biological backgrounds.

Materials and Methods {#epi412085-sec-0002}
=====================

This study was approved by the Institutional Review Board at Kyushu University (\#461‐00). Written informed consent was obtained from the parents. Experiments were conducted under a stringent compliance to the institutional guideline and our experimental protocol (23‐53). Case report and experimental procedures for whole‐exome sequencing (WES), in vitro conversion of neurons, quantitative polymerase chain reactions (PCR), and bioinformatics are presented in Appendix [S1](#epi412085-sup-0004){ref-type="supplementary-material"} and Figs. [S1](#epi412085-sup-0001){ref-type="supplementary-material"}, [S2](#epi412085-sup-0002){ref-type="supplementary-material"}).

Results {#epi412085-sec-0003}
=======

De novo mutations in *NF1* and *MAGEL2* {#epi412085-sec-0004}
---------------------------------------

De novo mutations in *NF1* ([NM001042492](NM001042492).2: c.4835 + 1G\>T) and *MAGEL2* ([NM019066.2](NM019066.2): c.219C\>G, c.224delC) were validated with Sanger sequencing (Figs. [1](#epi412085-fig-0001){ref-type="fig"}A,B). The former mutation occurred at the splicing junction of exon 36 in *NF1*, disrupting the functional expression of neurofibromin. The latter was mapped to the coding region of *MAGEL2* and was considered to produce a truncated form of MAGEL2. We further investigated whether the mutated allele was located on the paternal allele.[7](#epi412085-bib-0007){ref-type="ref"} Methylation‐sensitive digestion with *Sma*I followed by PCR amplification and direct sequencing of the flanking region revealed that the mutated allele remained intact after the *Sma*I digestion (Fig. [1](#epi412085-fig-0001){ref-type="fig"}B). We thus confirmed that the de novo *MAGEL2* mutation occurred at the maternal allele, which was fully methylated in lymphocytes. Microarray‐based comparative genome hybridization (CMA ver. 8.1 at Baylor MGL; data not shown) excluded that this case carried pathogenic copy number variants (CNVs).

![De novo mutations identified in the present case and functional interaction between *NF1* and *MAGEL2*. (**A**) *De novo* mutation at the splicing junction of exon 36 in *NF1*. The sequence chromatograms of father, mother, and the patient are shown. Red arrow indicates that this mutation occurred at chr17:29592358 ([NM_001042492](NM_001042492).2:c.4835 + 1G\>T). Boxed letters above the sequencing data denote exonic sequences. (**B**) *MAGEL2* mutation in the present case. Aligned data illustrate that the mutation occurred de novo in this patient at chr15:23892666, 23892671 ([NM_019066.4](NM_019066.4):c.219C\>G, c.224delC). Sequencing results before (*Sma*I^−^) and after the *Sma*I digestion (*Sma*I^+^) indicate that this mutation occurred at the methylated (or maternally inherited) allele. (**C**) *MAGEL2* mRNA expression before and after neuronal induction. White and black bar plots represent the relative expression levels in indicated cells from healthy controls (n = 9) and NF1 patients (n = 9), respectively. (**D**) *CYFIP1* and *UBE3A* expressions in fibroblasts and induced neurons. The gene expression profiles were quantitated in vitro using the cells from healthy controls and NF1 patients (n = 9 for each group). Values in C and D are shown as mean ± SD of each group. Asterisk indicates the p value of less than 0.05 (Student\'s t test).](EPI4-3-81-g001){#epi412085-fig-0001}

Functional interaction between NF1 and MAGEL2 {#epi412085-sec-0005}
---------------------------------------------

The de novo *MAGEL2* mutation in this case was unlikely a primary cause of the patient\'s developmental phenotypes. We considered the double mutations of *NF1* and *MAGEL2* as an extremely rare genetic event[8](#epi412085-bib-0008){ref-type="ref"} (Table [1](#epi412085-tbl-0001){ref-type="table-wrap"}). We alternatively interpreted this event to be possibly relevant with the unusual NF1 phenotype of this case. To explore whether NF1 and MAGEL2 might work as genetic modifiers for each other, we used STRING, a protein‐protein interaction database (<http://string-db.org/>). This open database predicted that NF1 and MAGEL2 were directly or indirectly connected via common binding proteins in a functional network consisting of 35 proteins (nodes) and 84 interactions (edges) (Fig. [S2](#epi412085-sup-0002){ref-type="supplementary-material"}A). Given the number of edges expected to be 48, these 35 proteins were considered to have 1.8‐fold enriched protein‐protein interactions (p = 2.25 × 10^−6^). Thus, this network was suggested to have functional enrichment in certain molecular pathways. Indeed, the Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) analyses showed that signaling molecules associated with "chromatin binding (GO:0003682)," "RNA polymerase (GO:0003899 and KEGG:3020)," and "RAS signaling pathways (KEGG:4014)" were enriched in this network (Figs. [S2](#epi412085-sup-0002){ref-type="supplementary-material"}B,C).

###### 

Clinical features of the present case in comparison with those of neurofibromatosis type 1 and Schaaf‐Yang syndrome

                                              Present case    Neurofibromatosis type 1   Schaaf‐Yang syndrome
  ------------------------------------------- --------------- -------------------------- ----------------------
  Mutated gene                                *NF1, MAGEL2*   *NF1*                      *MAGEL2*
  (Band Locus)                                                (17q11.2)                  (15q11.2)
  Phacomatosis and associated lesion                                                     
  Café‐au‐lait spots                          \+              \+                         −
  Neurofibroma                                \+              \+                         −
  Lisch nodules of iris                       −               \+                         −
  Dysmorphism                                                                            
  Bitemporal narrowing of facial appearance   −               −                          \+
  Almond‐shaped palpebral fissures            −               −                          \+
  Small hands                                 \+              −                          \+
  Joint contractures                          −               −                          \+
  Tumorigenesis and skeletal problem                                                     
  Brain tumor                                                                            
  Abnormal MRI signal                         \+              \+                         −
  Bone fracture                               −               \+                         −
  Neurological sign                                                                      
  Feeding problem                             −               −                          \+
  Hypotonia                                   \+              \+                         \+
  Developmental delay                         \+              \+                         \+
  Autism spectrum disorder                    \+              \+                         \+
  Seizure                                     \+              \+                         −
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Altered expression of MAGEL2 in NF1 patient‐derived neurons {#epi412085-sec-0006}
-----------------------------------------------------------

To validate the possible functional interplays between NF1 and MAGEL2, we examined whether pathogenic mutations in *NF1* might influence neuronal expression of *MAGEL2*. We determined the transcriptional activation of *NF1* and *MAGEL2* using the direct conversion system of fibroblast into neuron in vitro. Quantitative analyses on mRNA expression showed that *MAGEL2* expressions in fibroblasts did not differ between the patients and controls. The neuronal conversion induced robust increase in the *MAGEL2* expression (Fig. [1](#epi412085-fig-0001){ref-type="fig"}C). Notably, the neuronal expression of *MAGEL2* was decreased to 54% of that in healthy controls (n = 9 for each group, p = 0.0047, Student\'s t test; Fig. [1](#epi412085-fig-0001){ref-type="fig"}C). The neuronal expression of *MAGEL2* in the present case was 41% of that in healthy controls (p = 0.0189, Student\'s t test; data not shown). Neuronal conversion also induced higher expressions of imprinted genes (*UBE3A* and *CYFIP1*) at the chromosome 15p11.2 region than those in fibroblasts (Fig. [1](#epi412085-fig-0001){ref-type="fig"}D). However, induced neurons from NF1 patients and healthy controls expressed these genes at comparable levels. These data confirmed the epistatic regulation of *MAGEL2* expression by NF1 and illustrated the specific effects of the *NF1* mutations on transcriptional activation of *MAGEL2* during the neuronal conversion.

To test whether *NF1* mutations might affect other genes associated with EOEE, we randomly selected 6 EOEE‐associated genes (*CDKL5, CHD2, ARX*,*KCNT1*,*SCN1A,* and *TRIM8*)[9](#epi412085-bib-0009){ref-type="ref"}, [10](#epi412085-bib-0010){ref-type="ref"}, [11](#epi412085-bib-0011){ref-type="ref"}, [12](#epi412085-bib-0012){ref-type="ref"}, [13](#epi412085-bib-0013){ref-type="ref"} and assessed their expression profiles in both fibroblasts and induced neurons (Fig. [S3](#epi412085-sup-0003){ref-type="supplementary-material"}). As expected, in vitro conversion of fibroblasts into neurons resulted in 2‐ to 5‐fold higher expression of these six genes than those in fibroblasts. When we compared their expression levels in neurons, only *KCNT1* was expressed at a significantly lower level (69%) in NF1 neurons than that in healthy controls (p = 0.011, Student\'s t test; Fig. [S3](#epi412085-sup-0003){ref-type="supplementary-material"}). All the other genes were expressed in neurons from NF1 patients at similar levels to those in controls. These data suggested that *NF1* mutation attenuated the expression of a subset of EOEE‐associated genes.

Discussion {#epi412085-sec-0007}
==========

We presented a Japanese woman who had dysmorphic appearance, severe intellectual disability, and intractable epilepsy with a history of infantile‐onset seizures. This is the first case of NF1 carrying another de novo mutation in a gene that is known to cause different neurodevelopmental disorders. Previous studies demonstrated that NF1 patients are susceptible to the onset of epileptic encephalopathy, such as IS and EOEE.[14](#epi412085-bib-0014){ref-type="ref"}

The WES and subsequent analyses led us to the following two discussions: First, the severe phenotypes of this patient resulted solely from the *NF1* mutation regardless of the *MAGEL2* mutation. Second, the double mutations in *NF1* and *MAGEL2* exerted cumulative or synergistic effects to produce more severe phenotypes than those expected for individuals with a single gene mutation in either *NF1* or *MAGEL2*.

The first perspective might be valid taking the allele‐specific expression of *MAGEL2* into account. Indeed, truncating *MAGEL2* mutations proved to be critical for dysmorphic appearance and hypothalamic dysfunctions exclusively when the mutations occurred in the paternal alleles.[7](#epi412085-bib-0007){ref-type="ref"} Despite these facts, experimental studies have shown that *MAGEL2* was widely expressed in embryonic as well as in the adult brains.[15](#epi412085-bib-0015){ref-type="ref"} Moreover, allele‐specific expression of imprinted genes varies over time and by region in neuronal subpopulations.[15](#epi412085-bib-0015){ref-type="ref"} Recent studies have shown that *MAGEL2* and *NF1* were expressed from the maternal allele in embryonic tissues under certain conditions, suggesting that Prader‐Willi syndrome--associated genes in the chromosomal region at 15q11--q13 have epigenetic flexibility.[16](#epi412085-bib-0016){ref-type="ref"}, [17](#epi412085-bib-0017){ref-type="ref"} With our findings of lower expression of *MAGEL2* in neurons from NF1 patients, we considered that the *MAGEL2* mutation on the maternal allele caused only negligible effects on neuronal phenotype, whereas it could reach the pathogenic level when the additional mutation in *NF1* coincided. Therefore, it cannot be safely concluded that the *MAGEL2* mutation in the maternal allele was irrelevant to the neurodevelopmental phenotypes in this case.

MAGEL2 protein belongs to a family of melanoma‐associated antigen (MAGE) domain‐containing molecules, which has been characterized as highly expressed genes/proteins in various types of tumors.[18](#epi412085-bib-0018){ref-type="ref"} Among MAGE family proteins, NRAGE was shown to interact with p75 neurotrophin receptor and to promote nerve growth factor (NGF)‐dependent apoptosis, suggesting that NRAGE could be a component of intracellular signaling pathways.[19](#epi412085-bib-0019){ref-type="ref"} Similarly, NF1 is involved in the NGF‐dependent survival of embryonic sensory and sympathetic neurons.[20](#epi412085-bib-0020){ref-type="ref"} These data supported our hypothesis that MAGE family proteins and NF1 may cooperatively regulate the maturation of neurons under certain molecular pathways, as the network in this study illustrated.

The interaction database and subsequent bioinformatics analysis revealed that the NF1‐ and MAGEL2‐containing network was significantly enriched in the proteins associated with particular cellular functions, such as RAS signaling. Although physiological functions of MAGEL2 in neurons remain unknown, this result raised a new possibility that MAGEL2 may regulate the RAS signals cooperatively with NF1 in the developing brain. Thus, the hypomorphic mutations in the two genes may cause more profound effects on neuronal dysfunctions than those resulting from the mutation in either gene.

According to the protein interaction database, NF1 and MAGEL2 were unlikely to constitute a protein complex. Rather, our experimental data supported evidence that NF1 acts as an epistatic regulator of *MAGEL2* expression. In line with these data, we conceptualized that the de novo mutation of *MAGEL2* exaggerated neuronal dysfunctions owing to the *NF1* mutation and hyperactive RAS‐ERK signaling. Thus, the severe neurological phenotype of our case can be regarded as an extended model of digenic inheritance or the transheterozygote at two loci.[21](#epi412085-bib-0021){ref-type="ref"}, [22](#epi412085-bib-0022){ref-type="ref"} To determine their additive or synergistic effects on RAS signaling and neurological deficits, more studies using genetically engineered mice will be necessary.

Missing pieces are left for our future study to investigate whether and how recessive mutations inherited from the patient\'s parents could modify the phenotypes of other cases with atypical phenotypes of NF1. Accumulation of genome‐wide analysis data for NF1 patients with IS and EOEE will clarify these issues.
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**Figure S1**. Dysmorphic appearance of the present case.
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**Figure S2**. Bioinformatics analyses on interaction between *NF1* and *MAGEL2*.
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**Figure S3**. Expression of epileptic encephalopathy‐associated genes in fibroblasts and induced neurons.
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**Appendix S1**. Materials and methods.
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